Pregled bibliografske jedinice broj: 1030597
PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC
PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC // Annals of the Rheumatic Diseases
Madrid, Španjolska, 2019. str. 202-202 (predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1030597 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC
Autori
Khanna, Dinesh ; Lin, Celia J. F. ; Goldin, Jonathan ; Kim, Grace ; Kuwana, Masataka ; Allanore, Yannick ; Batalov, Anastas ; Butrimiene, Irena ; Carreira, Patricia ; Matucci-Cerinic, Marco ; Distler, Oliver ; Martinović Kaliterna, Dušanka ; Mihai, Carina ; Mogensen, Mette ; Olesińska, Marzena ; Pope, Janet ; Riemekasten, Gabriela ; Rodriguez-Reyne, Tatiana Sofía ; Santos, Maria Jose ; van Laar, Jacob M. ; Spotswood, Helen ; Siege, Jeffrey ; Jahreis, Angelika ; Furst, Daniel ; Denton, Christopher
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Annals of the Rheumatic Diseases
/ - , 2019, 202-202
Skup
Annual European Congress of Rheumatology, EULAR 2019
Mjesto i datum
Madrid, Španjolska, 12.06.2019. - 15.06.2019
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
LUNG FUNCTION, TOCILIZUMAB, SSc
Sažetak
The primary mRSS endpoint was not met ; however, TCZ Tx resulted in clinically relevant differences in FVC with preservation of LFS and improvement in fibrosis, measured by HRCT, in SSc pts.
Izvorni jezik
Engleski